HIMS Stock Faces Dual Blow From Expanded FTC Privacy Lawsuit After Selloff Driven By Q3 Subscriber Loss
HIMS Health (HIMS) cut its 2026 adjusted core profit guidance to $257–$277 million and revenue guidance to $3.13–$3.15 billion, citing subscriber losses. Q4 revenue is expected at $875–$895 million, below estimates. The stock has fallen 41% year-to-date, with mixed retail investor sentiment.
How this was made
The 30-second read
Why it matters
The guidance downgrade is likely to intensify selling pressure, especially in pre‑market trading, while the FTC lawsuit adds regulatory risk.
Market read
The news directly affects HIMS stock price and may influence sentiment in the broader health‑tech sector.
What to watch
The FTC privacy lawsuit could further impact valuation, but its resolution timeline is uncertain.
Background
Hims & Hers (HIMS) announced a third consecutive guidance cut for 2026 amid an expanded FTC privacy lawsuit and a 41% YTD share decline.
Ticker impact
Hims & Hers cut full‑year 2026 adjusted core profit guidance to $257‑$277 M and revenue guidance to $3.13‑$3.15 B, marking its third reduction this year.
downward pressure as investors price in lower profit and revenue expectations
Repeated guidance cuts typically trigger sell‑offs; the stock is already down 41% YTD, suggesting further downside risk.
Market effects
Potential drag on the telehealth/consumer health sector as peers may face similar profitability pressures.
Limited to U.S. markets; no broader regional effect.
Low global relevance beyond investors tracking U.S. health‑tech stocks.
Counterpoint
Some investors may view the lower guidance as a buying opportunity if the stock is oversold.
Key entities
- companyHims & Hers Health Inc.
U.S.-listed telehealth and consumer health company (ticker HIMS).
- regulatorFederal Trade Commission
U.S. agency expanding a privacy lawsuit against HIMS.
